- Advanced search
- Guide to IMMUNOPHARMACOLOGY Portal
|Approved drug?||Yes (FDA (2018))|
|International Nonproprietary Names|
|clone III | Emgality® | galcanezumab-gnlm | LY-2951742 | LY2951742|
|Galcanezumab (LY2951742) is a monoclonal antibody targeting calcitonin A and B (CALCA a.k.a. α-CGRP and CALCB a.k.a. β-CGRP respectively), whose anti-migraine and analgesic actions can be applied clinically.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Protein BLAST analysis reveals 100% matches with peptides claimed in patent WO2007076336 .
|GtoPdb PubChem SID||310264747|
|Search PubMed clinical trials||galcanezumab|
|Search PubMed titles||galcanezumab|
|Search PubMed titles/abstracts||galcanezumab|